Onconic Therapeutics (476060.KQ) said Thursday it presented large-scale real-world clinical study results for Jaqbo, a potassium-competitive acid blocker (P-CAB) class novel drug for gastroesophageal reflux disease (GERD), at Digestive Disease Week (DDW) 2026, the world's largest gastroenterology conference.
The study was conducted to reconfirm Jaqbo's efficacy and safety across diverse patient groups in actual clinical settings and to assess its potential to address unmet medical needs among patients whose symptoms had not improved with existing treatments. Onconic Therapeutics said the study carries significance as the first real-world data (RWD) evaluating the drug's objective efficacy and safety in a large patient population under actual prescribing conditions following its market launch.
The research analyzed objective therapeutic outcomes by tracking approximately 5,500 GERD patients who were prescribed 20 mg of Jaqbo Tab. for four weeks at around 300 private clinics (primary care institutions) in Korea between 2024 and 2025. Based on the Reflux Disease Questionnaire (RDQ, a 0-5 scale) that evaluates GERD symptoms such as heartburn and acid regurgitation, Jaqbo reduced the average score from 2.07 before administration to 0.44 after four weeks, a decrease of 1.63 points, statistically demonstrating symptom improvement.
Significant score reductions were also confirmed in patient groups whose symptoms had not improved despite taking conventional proton pump inhibitors (PPIs) or acid secretion inhibitors. This suggests Jaqbo's potential to improve symptoms unresolved by existing treatments in actual clinical settings. Of all patients, 93.4% responded that they were "satisfied" or "very satisfied" with the treatment's effectiveness, while the incidence of adverse drug reactions (ADRs) was only 0.05%. Patients cited the drug's most significant competitive advantages as its convenient administration regardless of meals and its ability to improve symptoms unresolved by existing medications within four weeks.
Onconic Therapeutics concluded the study demonstrates that "switch therapy" to Jaqbo can be an effective strategy for patients with a history of using PPIs and acid secretion inhibitors. "The effectiveness of the Jaqbo Tab. switch therapy strategy has been proven through large-scale data, enabling us to provide a new prescription option for GERD patients," a company official said. "Based on these research findings, we will expand Jaqbo's achievements in both domestic and overseas markets."
